Literature DB >> 25861784

NK-1 Antagonists and Itch.

Sonja Ständer1, Thomas A Luger.   

Abstract

Substance P (SP) is an important mediator of pro-inflammatory mechanisms in the skin. It targets multiple cells such as keratinocytes, mast cells, and fibroblasts which are involved in the cutaneous generation of pruritus. This suggests that SP is an interesting target for therapy. In fact, in recent case reports and case series, SP antagonists demonstrated a significant antipruritic effect in acute and chronic pruritus such as drug-induced pruritus, paraneoplastic pruritus, prurigo nodularis, cutaneous T-cell lymphoma, and brachioradial pruritus.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25861784     DOI: 10.1007/978-3-662-44605-8_14

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  12 in total

Review 1.  [New treatment options for chronic pruritus].

Authors:  C Zeidler; B Pfleiderer; S Ständer
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751

2.  The Neurokinin-1 Receptor is Expressed with Gastrin-Releasing Peptide Receptor in Spinal Interneurons and Modulates Itch.

Authors:  Tayler D Sheahan; Charles A Warwick; Louis G Fanien; Sarah E Ross
Journal:  J Neurosci       Date:  2020-10-13       Impact factor: 6.167

Review 3.  [Treatment of chronic pruritus-what is new?]

Authors:  C Zeidler; M Metz; S Steinke; S Ständer
Journal:  Hautarzt       Date:  2018-08       Impact factor: 0.751

Review 4.  Chronic Pruritus: Current and Emerging Treatment Options.

Authors:  Manuel P Pereira; Sonja Ständer
Journal:  Drugs       Date:  2017-06       Impact factor: 11.431

Review 5.  Looking forward to new targeted treatments for chronic spontaneous urticaria.

Authors:  Emek Kocatürk; Marcus Maurer; Martin Metz; Clive Grattan
Journal:  Clin Transl Allergy       Date:  2017-01-10       Impact factor: 5.871

Review 6.  Focus on the role of substance P in chronic urticaria.

Authors:  Gino A Vena; Nicoletta Cassano; E Di Leo; G F Calogiuri; Eustachio Nettis
Journal:  Clin Mol Allergy       Date:  2018-11-19

Review 7.  NK-1 Receptor Antagonists and Pruritus: Review of Current Literature.

Authors:  Marcelina Pojawa-Gołąb; Kamila Jaworecka; Adam Reich
Journal:  Dermatol Ther (Heidelb)       Date:  2019-06-12

8.  Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.

Authors:  Bruno Vincenzi; Mike Trower; Ajay Duggal; Pamela Guglielmini; Peter Harris; David Jackson; Mario E Lacouture; Emiliangelo Ratti; Giuseppe Tonini; Andrew Wood; Sonja Ständer
Journal:  BMJ Open       Date:  2020-02-06       Impact factor: 2.692

Review 9.  Advances in understanding itching and scratching: a new era of targeted treatments.

Authors:  Kristen M Sanders; Leigh A Nattkemper; Gil Yosipovitch
Journal:  F1000Res       Date:  2016-08-22

Review 10.  Aprepitant for the Treatment of Chronic Refractory Pruritus.

Authors:  Alice He; Jihad M Alhariri; Ronald J Sweren; Madan M Kwatra; Shawn G Kwatra
Journal:  Biomed Res Int       Date:  2017-09-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.